DUBLIN – The steady flow of capital into early stage biopharmaceutical innovation continues unabated, as evidenced by two separate transactions disclosed Wednesday. Astrazeneca plc's Medimmune arm is spinning out a series of pipeline assets into a new venture, Viela Bio Inc., which has secured funding commitments of up to $250 million from a syndicate of investors led by three funds with a strong Chinese orientation.